US court declares MorphoSys patents invalid

Saturday 26 January 2019


A US district court has ruled against MorphoSys AG in a patent infringement suit that the Germany company brought against Genmab A/S and its partner Janssen Biotech Inc relating to Darzalex (daratumumab), their marketed drug for multiple myeloma.

Read in full with a subscription

Learn more about subscribing to MedNous.